Lawrence, KS, United States of America

Ronald T Borchardt

This inventor holds 7 USPTO granted patents and 4 published patent applications and 2 EPO patents. Top assignees: Onyx Therapeutics, Inc., Proteolix, Inc., University of Kansas. Active years: 1989-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ronald T Borchardt. Retrieved from https://idiyas.com/inventor/ronald-t-borchardt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 85.7

 

Average Co-Inventor Count = 4.7

ph-index = 7

Forward Citations = 263(Granted Patents)


Company Filing History:


Years Active: 1989-2012

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Journey of Ronald T Borchardt

Introduction:

Ronald T Borchardt, a distinguished inventor hailing from Lawrence, Kansas, has made significant contributions to the field of innovations and patents.

Latest Patents:

Ronald T Borchardt holds several patents in the pharmaceutical and medical research sectors, showcasing his commitment to advancing technology and healthcare.

Career Highlights:

With a career spanning over three decades, Ronald T Borchardt has been a trailblazer in developing cutting-edge solutions in drug delivery systems and bioavailability enhancement techniques.

Collaborations:

Throughout his career, Ronald T Borchardt has collaborated with leading research institutions, pharmaceutical companies, and universities to bring his inventions to life and make a lasting impact on the industry.

Conclusion:

In conclusion, Ronald T Borchardt's innovative spirit and dedication to pushing the boundaries of science have solidified his reputation as a pioneering inventor in Lawrence, Kansas, and beyond.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…